TY - JOUR
T1 - Economic evaluation of intravenous immune globulin therapy for Kawasaki syndrome
AU - Klassen, Terry P.
AU - Rowe, Peter C.
AU - Gafni, Amiram
N1 - Copyright:
Copyright 2014 Elsevier B.V., All rights reserved.
PY - 1993/4
Y1 - 1993/4
N2 - Objective: To determine the costs and clinical outcomes of three alternative treatments of the acute phase of Kawasaki syndrome: aspirin alone; low doses of intravenously administered immune globulin (IVIG-LD), 400 mg/kg per dose for 4 days; and high doses of intravenously administered immune globulin (IVIG-HD), 2.0 gm/kg for one dose. Design: A model was developed that assumed the inclusion of 100 patients with acute Kawasaki syndrome in each treatment option. Costs were valued by using the Chedoke-McMaster Corporate Cost Model in 1992 Canadian dollars. Clinical outcome, based on the published literature, was measured by the prevalence of coronary artery dilation at 7 weeks from the diagnosis of Kawasaki syndrome. Results: For every 100 patients with Kawasaki syndrome, the cost was reduced by $323,400 when aspirin therapy alone was changed to VIG-HD therapy and 14 cases of coronary artery dilation were therepy prevented. When IVIG-HD therapy was compared with IVIG-LD therapy, the cost was reduced by $118,200 because two cases of coronary artery aneurysm were prevented. This latter result was sensitive to the duration of hospitalization, with IVIG-HD costing $8500 more for every 100 patients than IVIG-LD when it was assumed that both groups were hospitalized for 5 days, an unlikely occurrence. Conclusions: Treatment with IVIG-HD for Kawasaki syndrome is preferred because it results in both lower costs and lower rates of coronary artery dilation.
AB - Objective: To determine the costs and clinical outcomes of three alternative treatments of the acute phase of Kawasaki syndrome: aspirin alone; low doses of intravenously administered immune globulin (IVIG-LD), 400 mg/kg per dose for 4 days; and high doses of intravenously administered immune globulin (IVIG-HD), 2.0 gm/kg for one dose. Design: A model was developed that assumed the inclusion of 100 patients with acute Kawasaki syndrome in each treatment option. Costs were valued by using the Chedoke-McMaster Corporate Cost Model in 1992 Canadian dollars. Clinical outcome, based on the published literature, was measured by the prevalence of coronary artery dilation at 7 weeks from the diagnosis of Kawasaki syndrome. Results: For every 100 patients with Kawasaki syndrome, the cost was reduced by $323,400 when aspirin therapy alone was changed to VIG-HD therapy and 14 cases of coronary artery dilation were therepy prevented. When IVIG-HD therapy was compared with IVIG-LD therapy, the cost was reduced by $118,200 because two cases of coronary artery aneurysm were prevented. This latter result was sensitive to the duration of hospitalization, with IVIG-HD costing $8500 more for every 100 patients than IVIG-LD when it was assumed that both groups were hospitalized for 5 days, an unlikely occurrence. Conclusions: Treatment with IVIG-HD for Kawasaki syndrome is preferred because it results in both lower costs and lower rates of coronary artery dilation.
UR - http://www.scopus.com/inward/record.url?scp=0027398892&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027398892&partnerID=8YFLogxK
U2 - 10.1016/S0022-3476(05)83532-2
DO - 10.1016/S0022-3476(05)83532-2
M3 - Article
C2 - 8463897
AN - SCOPUS:0027398892
SN - 0022-3476
VL - 122
SP - 538
EP - 542
JO - The Journal of pediatrics
JF - The Journal of pediatrics
IS - 4
ER -